BMC Pulmonary Medicine (Jul 2023)

Association between intrapleural urokinase monotherapy and treatment failure in patients with pleural infection: a retrospective cohort study

  • Jumpei Taniguchi,
  • Hiroki Matsui,
  • Tatsuya Nagai,
  • Ayumu Otsuki,
  • Hiroyuki Ito,
  • Hiroshi Sugimura,
  • Kei Nakashima

DOI
https://doi.org/10.1186/s12890-023-02559-5
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Pleural infection, an infection of the pleural space, is frequently treated with antibiotics and thoracic tube drainage. In case of insufficient drainage, an intrapleural fibrinolytic agent is considered before surgical intervention. However, the effectiveness of fibrinolytic monotherapy is still controversial. Therefore, we aimed to examine the association between urokinase monotherapy and treatment failure in patients with pleural infection. Methods In this retrospective observational study, patients with pleural infection underwent chest tube insertion were divided into two groups including patients treated with or without intrapleural instillation of urokinase. The propensity score overlap weighting was used to balance the baseline characteristics between the groups. Treatment failure was defined by the composite primary outcome of in-hospital death and referral for surgery. Results Among the 94 patients, 67 and 27 patients were in the urokinase and non-urokinase groups, respectively. Urokinase monotherapy improved the composite outcome between the groups (19.4% vs. 48.1%, p = 0.01). After adjusting using propensity score overlap weighting, urokinase monotherapy improved the composite outcome compared to the non-urokinase group (19.0% vs. 59.5%, p = 0.003). Conclusions Urokinase monotherapy can be an important nonsurgical treatment option for patients with pleural infection. Trial registration The participants were retrospectively registered.

Keywords